An Open, Randomised, 2-way Crossover Study to Establish the Absolute Bioavailability of AZD9056 in Tablet Formulation (200 mg) Compared With and Intravenous Formulation (25 mg), in Healthy Volunteers

Study identifier:D1520C05285

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open, Randomised, 2-way Crossover Study to Establish the Absolute Bioavailability of AZD9056 in Tablet Formulation (200 mg) Compared With and Intravenous Formulation (25 mg), in Healthy Volunteers

Medical condition

Rheumatoid Arthritis

Phase

Phase 1

Healthy volunteers

-

Study drug

-

Sex

-

Actual enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Sept 2002
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria